Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could exercise be a new way to clear lungs in PCD?

NCT ID NCT07699302

Knowledge-focused Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at how exercise and a saltwater mist (hypertonic saline) affect mucus clearance in people with primary ciliary dyskinesia (PCD), a rare lung condition where tiny hairs in the airways don't work properly. Researchers will measure how fast the lungs clear inhaled particles during and after exercise, and whether adding hypertonic saline boosts that effect. The goal is to understand non-ciliary clearance mechanisms, which could lead to new treatments for mucus buildup in lung diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypertonic saline
What this could lead to
If successful, this research could point toward exercise-based or hydration-based therapies to improve lung clearance in people with muco-obstructive lung diseases.
What could go wrong
This is a very small pilot study with only 8 participants, so results may not apply broadly. The effects measured are exploratory and may not lead to clear treatment benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 8 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or older * Diagnosis of PCD with supporting genetics * Lung function with forced expiratory volume in 1 second (FEV1) percent predicted \>30% * Ability to exercise for 20 minutes (Exercise Assessment performed at screening visit) Exclusion Criteria: * Intolerance to 7% HS * Failure of HS tolerance test (HSTT) at visit 1 (V1), defined as a decline of 10% in FEV1 from baseline pre-bronchodilator (BD) FEV1 after 7% HS * Intolerance to levalbuterol * Exercise-induced asthma * Complex congenital heart disease or other exercise limitation * Lung transplantation or listed for lung transplantation * History of lung resection of the lung analyzed by MCC (depending on situs status) * Pregnancy or unwillingness to use approved birth control during study period * Recent hemoptysis (\>60 ml in the last 3 months) * Pulmonary exacerbation in preceding 4 weeks * Change in pulmonary therapies within preceding 4 weeks * Resting or exertional O2 requirement (nocturnal acceptable) * Tobacco / smoking history (any within last year, and \>10 pack year history in past) * More than 2 chest computed tomography (CT) scans in the past year or a combination of procedures believed to have exposed the lungs to \>150 millisieverts (mSv), including from other research studies * Participation in another interventional trial within 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity premature centromere division primary ciliary dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCD Primary ciliary dyskinesia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27278, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.